Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Kevin B. Kim et al.|The Lancet Oncology|2012Cited by 541
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Ingrid A. Mayer et al.|Journal of Clinical Oncology|2017Cited by 407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Wells A. Messersmith et al.|Annals of Oncology|2021Cited by 371
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J. Ocean, David M. Goldenberg, Alexander Starodub et al.|Cancer|2017Cited by 235
KRAS MutationWilbur A. Franklin, Wells A. Messersmith|Journal of Molecular Diagnostics|2009Cited by 110